Dr. Julie Kanter is the Associate Professor of hematology and oncology and Director of the Comprehensive Sickle Cell Center at the University of Alabama at Birmingham. Her academic focus is on improving the comprehensive care of persons with sickle cell disease throughout the lifespan and clinical and translational research to better understand and address issues in treatment and prevention in sickle cell disease.

Prior to moving to Alabama, Dr. Kanter was the Director of sickle cell disease research and Associate Professor of Pediatrics at the Medical University of South Carolina. Dr. Kanter is very committed to improving outcomes in sickle cell disease and ensuring those outcomes reach the affected individuals. She works closely with national partners including the American Society of Hematology and the NIH on both advocacy and research.

Board Certification:

– Pediatrics: Pediatric Hematology-Oncology

Specialties:

– Pediatric Hematology/Oncology

– Cancer

– Pediatric

Representative Publications:

Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

Increased prevalence of potential right-to-left shunting in children with sickle cell anaemia and stroke

Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events

Regional- and Age-Related Differences in Pain in Children with Sickle Cell Anemia: Results from the Multinational DOVE Study

Share

Discuss in Social Wall

Twitter

Share to SCDteam

+myBinder